MedTrace Logo

Levetiracetam (Keppra) to Improve Chronic Aphasia in Post-stroke Patients.

NCT00227461 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-02-17

No results posted yet for this study

Summary

The study investigates the possibility that levetiracetam may improve the symptoms of chronic post-stroke aphasia.

Conditions

Interventions

DRUG

Wait first, then levetiracetam

Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.

DRUG

Levetiracetam first, then wait

subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design

Sponsors & Collaborators

  • UCB Pharma

    collaborator INDUSTRY

  • Kessler Foundation

    lead OTHER

Principal Investigators

  • A.M. Barrett, MD · Kessler Foundation

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00227461 on ClinicalTrials.gov